Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KYAT1 | Q16773 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6141984 | 1.00 | POLB (0.54) | POLBKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL16855424 | 1.00 | POLB (0.54) | POLBKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL4408498 | 0.88 | TSHR (0.50) | KMT2AMEN1ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL4395363 | 0.88 | MEN1 (0.44) | POLBKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL19342014 | 0.88 | MEN1 (0.44) | POLBKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL19341959 | 0.88 | TSHR (0.50) | KMT2AMEN1ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL22621727 | 0.88 | TSHR (0.50) | KMT2AMEN1ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL11765704 | 0.87 | POLB (0.55) | POLBKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL13901605 | 0.87 | POLB (0.55) | POLBKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL11765700 | 0.87 | POLB (0.55) | POLBKMT2AMEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373204-B1 | HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-1551406-A1 | USE OF INDOLYL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ALLERGIC RHINITIS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-13 | — | — | EP | disclosed |
| US-20050085487-A1 | Heterocyclic compounds | CARRUTHERS NICHOLAS I (US) | 2005-04-21 | — | — | US | disclosed |
| US-6803362-B2 | ANTIHISTAMINES SUCH AS (5-CHLORO-1H-INDOL-2-YL)-(4-METHYL-PIPERAZIN-1-YL)-METHANONE, USED AS ANTIINFLAMMATORY, ANTIARTHRITIC OR BRONCHODILATOR AGENTS AND/OR IMMUNOLOGY MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL INC. | 2004-10-12 | — | — | US | disclosed |
| US-20040132715-A1 | Method to treat allergic rhinitis | DUNFORD PAUL J (US) | 2004-07-08 | — | — | US | disclosed |
| WO-2004022061-A1 | USE OF INDOLYL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT ALLERGIC RHINITIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | disclosed |
| EP-1373204-A2 | HETEROCYCLIC COMPOUNDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030207893-A1 | Heterocyclic compounds | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2002072548-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS HISTAMINE H4 LIGANDS. | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132715-A1 | Method to treat allergic rhinitis | HRH2, HRH4, HRH1 | POLB 3528/4885KMT2A 2116/4885MEN1 3633/4885 |
| US-20050085487-A1 | Heterocyclic compounds | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1 | POLB 1187/4885KMT2A 1652/4885MEN1 745/4885 |
| US-20030207893-A1 | Heterocyclic compounds | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1 | POLB 1188/4885KMT2A 1661/4885MEN1 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.